Drug Profile
Research programme: fixed combinations for cardiovascular indications - HanAll Biopharma
Alternative Names: HL013 (hypertension/hyperlipidemia functional combination) - HanAll Biopharma; HL037; HL053; HL162Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator HanAll Biopharma
- Class
- Mechanism of Action Angiotensin type 2 receptor antagonists; Calcium channel antagonists; HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Hyperlipidaemia; Hypertension
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Hyperlipidaemia in South Korea (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Hypertension in South Korea (PO)
- 08 Feb 2011 This programme is ongoing in South Korea